 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3388 News |  |
| «12...2021222324252627282930...4849» |
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Review, Journal: Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis. (Pubmed Central) - Apr 30, 2022
The findings suggest that patients in the CAZ-AVI group had a significantly lower 30-day mortality than any other regimens and than colistin-based regimens. This paper provides a rationale for the use of CAZ-AVI in one of the most urgent antimicrobial-resistant infections of CRE bloodstream infections.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains. (Pubmed Central) - Apr 30, 2022
KPC-93 possessed a five-amino-acids insertion (Pro-Asn-Asn-Arg-Ala) between Ambler positions 267 and 268 in KPC-2. Our findings have revealed the potential risk of bla gene mutations associated with CZA exposure over a short period of time.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Emergence of Hypervirulent ST11-K64 Klebsiella pneumoniae Poses a Serious Clinical Threat in Older Patients. (Pubmed Central) - Apr 29, 2022
In conclusion, higher MICs of the last line antibiotic agents (ceftazidime-avibactam, tigecycline) might be a critical consideration in the clinical management of older patients where the concentration of these toxic antibiotics matters because of underlying comorbidities. Caution regarding KPC-2-producing ST11-K64 CR-hvKP as being new significant "superbugs" is required as they are widespread, and infection control measures should be strengthened to curb further dissemination in nosocomial settings in China.
- ||| aztreonam / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
If I understand correctly, it is a urine with 80000 cgi/ml of Pyo and a metallo- b-lactamase. Aztreonam+ceftazidime-avibactame or cefiderocol would likely be the best options. Catheter in place or other plastic that can be changed? (Twitter) - Apr 27, 2022
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Evaluation of the VITEK2 AST-XN17 card for the detection of carbapenemase-producing Enterobacterales in isolates primarily producing metallo β-lactamase. (Pubmed Central) - Apr 27, 2022
The sensitivity and specificity of each card in the AES output were 86.2% and 94.7% for AST-N404 and AST-XN17 and 91.5% and 90.8% for AST-N268 and AST-XN17, respectively. AST using the VITEK2 AST-XN17 card is a useful test method of screening for CPE.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Journal: Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. (Pubmed Central) - Apr 27, 2022
In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem. (Pubmed Central) - Apr 27, 2022
All OXA-48-like producers remained susceptible to ceftazidime-avibactam. We showed that in vitro inoculum effect was observed with meropenem but not with CZA for OXA-48- combined with CTX-M-producing Enterobacterales.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: A general guidance for clinical microbiology laboratories in India. (Pubmed Central) - Apr 26, 2022
Various methods such as broth disk elution, disk stacking, gradient strip stacking, and strip crossing have been proposed for testing this combination. Among them, broth disk elution and strip based testing methods showed good correlation with the broth micro-dilution method.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Effects of preservative fluid associated possible donor-derived carbapenem-resistant Klebsiella Pneumoniae infection on kidney transplantation recipients. (Pubmed Central) - Apr 26, 2022
Among them, broth disk elution and strip based testing methods showed good correlation with the broth micro-dilution method. This study shows that the incidence of pdd-CRKP is high in our centre, recipients with pdd-CRKP infection can still achieve a good prognosis with the use of antimicrobial agents including CAZ-AVI.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Negaban (temocillin) / Eumedica, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. (Pubmed Central) - Apr 24, 2022
In diffusers, stability times vary from 6 h for cefiderocol, 8 h for ceftazidime, 12 h for ceftazidime/avibactam and ceftolozane/tazobactam (NS), 24 h for temocillin (NS) and piperacillin/tazobactam (D5W), up to 48 h for aztreonam and vancomycin. Solutions stored at 37 °C are less stable and allow the administration of seven antibiotics using diffusers.
- || PK/PD data, Review, Journal: Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. (Pubmed Central) - Apr 24, 2022
Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.
- | imipenem/relebactam / Merck (MSD)
Journal: Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. (Pubmed Central) - Apr 24, 2022
Although treatment with CAZ-AVI and gentamicin completely eradicated the infection due KPC-Kp cross-resistance to IMI-REL and MER-VAB, the patient became colonized subsequently by KPC-Kp strains susceptible to IMI-REL and MER-VAB...Phylogenetic analysis demonstrated that KPC-Kp cross-resistance to IMI-REL and MER-VAB was clonally related to a KPC-Kp resistant to IMI-REL as previously described, demonstrating the spread of this multidrug resistant clone in the hematological unit. In conclusion, the results presented in this study reported the emergence of cross-resistance to MER-VAB and IMI-REL in a KPC-Kp strain isolated from a hematological patient and highlight the potential development and diffusion of new multidrug resistance traits.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Test for Enterobacterales-Containing Blood Cultures in China. (Pubmed Central) - Apr 23, 2022
In addition, we developed potential breakpoints for a recently introduced antimicrobial, 30/20 μg ceftazidime-avibactam, which has high potential for treating multidrug-resistant Enterobacterales...The breakpoints developed in this study can categorize the isolates sampled in this study with an accuracy of 93%. Results from our experiments can be applied to clinically determine the microbial susceptibility of BSI-causing bacteria within 8 h and benefit clinical diagnostics for BSI patients.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: Dr. Oliva now presents on use of fosfomycin added to ceftazidime-avibactam for kpc BSI Case-control (n=116) Overall mortality similar Attributable mortality lower in fosfomycin combination #ECCMID2022 (Twitter) - Apr 23, 2022
- | Journal: Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. (Pubmed Central) - Apr 22, 2022
Conventionally used antibiotics (polymyxins, tigecycline, aminoglycosides, etc.) are associated with poor efficacy and toxicity profiles are quite worrisome...A review of novel β-lactam/β-lactamase inhibitors (BLI) recently approved and in clinical development as well as cefiderocol, eravacycline and apramycin are discussed...Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam are novel agents with favorable outcome and associated with improved mortality in KPC-producing K. pneumoniae infections...Novel BLI in later stage of development i.e., aztreonam-avibactam, cefepime-zidebactam, cefepime-taniborbactam and meropenem-nacubactam as well as cefiderocol are active in vitro against both KPC and MBL. Potential expectations of future therapeutic strategies are improved potency against CPKP, more tolerable safety profile and capability of overcoming current resistance mechanism of multidrug-resistant K. pneumoniae.
- | Journal: Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam. (Pubmed Central) - Apr 22, 2022
The V239G variant does not generate collateral β-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β-Lactamase. (Pubmed Central) - Apr 22, 2022
Based upon these observations, we discuss the impact of disordering of the Ω loop as a consequence of the D179Y substitution. These conformational changes and disorder in the overall structure as a result of D179Y contribute to this unanticipated phenotype.
- | Journal: Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa. (Pubmed Central) - Apr 22, 2022
The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-β-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum β-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. (Pubmed Central) - Apr 22, 2022
To understand why the β-lactamase inhibitor vaborbactam is less affected by the D179 variants than avibactam, we determined the crystal structure of D179N KPC-2 in complex with vaborbactam, which revealed wild-type KPC-2-like vaborbactam-active site interactions. Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Ω loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Rapid Desensitization after a Type I Hypersensitivity Reaction to Ceftazidime/ Avibactam. (Pubmed Central) - Apr 22, 2022
Drug desensitization procedures are useful for patients with adverse drug reactions in which optimal alternatives are not available. This is the first case report demonstrating a successful rapid induction of tolerance for the antibiotic ceftazidime/avibactam.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
@NICEComms impresses again with its transparency. The assessments of cefiderocol and ceftazidime/avibactam are worth reading, giving important insights into new methods for health technology assessment. Well done and thanks! @LeonardColm and Dr. Nick Crabb (Twitter) - Apr 22, 2022
- | Journal: New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. (Pubmed Central) - Apr 21, 2022
The approved antibiotics include ceftobiprole, ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol. Their major advantages include their high activity against multidrug-resistant gram-negative pathogens.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: When More is Still Not Enough: A Case of Ceftazidime-Avibactam Resistance in a Burn Patient. (Pubmed Central) - Apr 19, 2022
Repeat blood cultures demonstrated a multidrug resistant (MDR) Pseudomonas with a minimum inhibitory concentration (MIC) to ceftazidime-avibactam of 16mcg/mL, which is above the Clinical and Laboratory Standards Institute (CLSI) breakpoint of 8mcg/mL. At first, resistance was thought to have occurred due to inadequate dosing, but genetic work demonstrated multiple genes encoding beta-lactamases.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Ceftazidime-avibactam for the Treatment of Multidrug-resistant Pseudomonas aeruginosa Central Nervous System Infection in Pediatric Patient: a Case Report. (Pubmed Central) - Apr 15, 2022
CSF cultures became sterile 3 days after initiation of this antibiotic regimen, and subsequent CSF cultures had no growth. No recurrent episode of central nervous system infections due to P. aeruginosa occurred up to 2 years of follow-up.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Analysis of the clinical application of ceftazidime-avibactam in China. (Pubmed Central) - Apr 15, 2022
Our results showed that ceftazidime-avibactam might be a potencial choice for the MDR-GNB infections. However, further research are still needed to identify its efficacy and safety in the real world.
- | Preclinical, Journal: In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates. (Pubmed Central) - Apr 14, 2022
Susceptibility for comparators ranged from 24.0% for meropenem to 91.3%, 92.3% and 96.1% for imipenem-relebactam, ceftazidime-avibactam and meropenem-vaborbactam, respectively; 48.1%, 75.2% and 79.8% of the isolates were susceptible to omadacycline, colistin and eravacycline, respectively. Two isolates with cefiderocol MICs of 2 mg/L had mutations or deletions of the iron transport genes fhuA/E or fepA, as determined by WGS.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019. (Pubmed Central) - Apr 14, 2022
NDM was predominantly identified in 68% of the E. coli isolates followed by OXA-48 like in 24% isolates. The findings suggest that ceftazidime- avibactam is a reasonable alternative to standard therapy for management of carbapenem resistant Enterobacterales infections particularly with K. pneumoniae and E. coli with the OXA-48 like genotype.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Off-Label Use of Ceftazidime-Avibactam in a Premature Infant With Multidrug-Resistant Klebsiella pneumoniae Infection: A Case Report. (Pubmed Central) - Apr 14, 2022
The findings suggest that ceftazidime- avibactam is a reasonable alternative to standard therapy for management of carbapenem resistant Enterobacterales infections particularly with K. pneumoniae and E. coli with the OXA-48 like genotype. Treatment with CAZ-AVI was safe and effective in our patient.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), trimethoprim/sulfamethoxazole / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Is it susceptible to ceftazidime-avibactam? Do you have ceftolozane-tazobactam? What's the Bactrim for? (Twitter) - Apr 12, 2022
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Thanks, @wfwrighID. The probable source is intraabdominal, second place possible is urinary system. This isolate is unfortunately pan-resistant, the testing for ceftazidime-avibactam is in progress (the result is expected tommorow). (Twitter) - Apr 12, 2022
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: The preliminary result of susceptibility testing (only disk diffusion available) for ceftazidime-avibactam was intermediate resistance, so lab is checking again. I suggested dual carbapenem therapy for this patient until ceftazidime-avibactam testing was available. (Twitter) - Apr 12, 2022
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
PK/PD data, Journal: Efficacy and Pharmacodynamic Target Attainment for Ceftazidime-Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports. (Pubmed Central) - Apr 9, 2022
In addition, we described another case on continuous venovenous hemodialysis (CVVHD), in which CZA was administered as 2.5 g q12h in 2-h infusions. The dose regimen for these two cases could achieve trough concentration of ceftazidime higher than fourfold of the MIC and trough concentration of avibactam higher than the threshold of 1 μg/mL during the treatment, and exert efficient antimicrobial effect.
- | amikacin/fosfomycin inhalation (AFIS) / Savara, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Prediction of Prognosis in Adult Patients With Carbapenem-Resistant Klebsiella pneumoniae Infection. (Pubmed Central) - Apr 6, 2022
Tigecycline improved the treatment efficiency in 7 days, but a trend toward increased mortality was seen (HR, 1.69; 95% CI: 0.98-2.94; P = 0.061). The antimicrobial regimen efficacy data and the predictive nomogram established in this study can help clinicians in identifying high-risk adult patients with CRKP infection, improving the therapeutic effect, and reducing mortality.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: A Novel Nomogram for Predicting Risk Factors and Outcomes in Bloodstream Infections Caused by Klebsiella pneumoniae. (Pubmed Central) - Apr 6, 2022
Tigecycline resulted in higher mortality for patients with BSI-KP. Rational use of nomograms may help clinicians make better Clinical decisions when treating BSI-KP patients.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Clinical Characteristics and Resistance Patterns of Pseudomonas aeruginosa Isolated From Combat Casualties. (Pubmed Central) - Apr 5, 2022
Among MDR P. aeruginosa, active antimicrobials remain the oldest and most toxic. Despite ongoing efforts, outbreaks are still noted, reinforcing the crucial role of antimicrobial stewardship and infection control.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Multidisciplinary Approach to Multiple Multiresistant Agent Infection of Instrumented Spine Surgery: A Case Report. (Pubmed Central) - Apr 5, 2022
Care should be taken to avoid their emergence, but when present, a multidisciplinary approach is mandatory to ensure clinically up-to-date treatment choices. Multimodal antibiotic schemes tend to show the most promising results, with which successful infection resolution can still be achieved.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015-2019. (Pubmed Central) - Apr 5, 2022
Ceftazidime/avibactam also achieved the second highest activity result against P. aeruginosa strains (including MDR and CR phenotypes). These results are much higher when excluding MBL-positive isolates that exhibit intrinsic resistance to ceftazidime/avibactam.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. (Pubmed Central) - Apr 5, 2022
Ceftazidime-avibactam is a last-resort antibiotic against GNB of Ambler class A/C/D enzyme-producers and a majority of CR-P...Furthermore, ceftolozane-tazobactam is shown to exhibit excellent in vitro activity against CR- and XDR-P...baumannii complex isolates. In this era of antibiotic pipelines, strict implementation of antibiotic stewardship is as important as in-time isolation cohorts in limiting the spread of CR/XDR-GNB and alleviating the worsening trends of resistance.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
I like to say cefto-tazo and ceftaz-avi, but I have nothing for the others. Agree those sound like jibberish! (Twitter) - Apr 2, 2022
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Successful treatment of Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime/avibactam and aztreonam. (Pubmed Central) - Apr 2, 2022
Fourteen weeks after the accident the patient was discharged. After 2 months of follow-up neither relapses nor reinfections have been reported.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Does the use of new cephalosporins follow the authorised, financed and approved indications? A study of their use in routine clinical practice in a tertiary hospital. (Pubmed Central) - Apr 2, 2022
After 2 months of follow-up neither relapses nor reinfections have been reported. Our results highlight the importance of stewardship programmes in the decision-making process and in the follow-up of patients with infections caused by MDR microorganisms.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Observational data, Journal: Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020-21. (Pubmed Central) - Apr 2, 2022
ST147 ESBL-producing hvKp is associated with high mortality in COVID-19 patients. Strict microbiological surveillance and infection control measures are needed in this population.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Outbreak of ceftazidime-avibactam resistant KPC-producing Klebsiella pneumoniae in a COVID-19 Intensive Care Unit, Italy: urgent need for updating diagnostic protocols of surveillance cultures. (Pubmed Central) - Apr 2, 2022
Strict microbiological surveillance and infection control measures are needed in this population. No abstract available
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM. (Pubmed Central) - Apr 1, 2022
No abstract available CAZ-AVI + metronidazole proved to be an effective option for critical patients with complicated intra-abdominal infection and can be considered as an alternative to carbapenems in the ICU setting for the treatment of resistant pathogens.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Klebsiella pneumoniae resistente ai carbapenemici: prevalenza delle infezione ematiche prima e dopo la pandemia da SARS-CoV-2 in un ospedale di livello terziario del Nord-Est italiano. (Pubmed Central) - Apr 1, 2022
In questo studio siamo andati a valutare, nel nostro ospedale, come è cambiata la prevalenza delle infezioni ematiche da Klebsiella pneumoniae resistente ai carbapenemici nel periodo 2019-primo quadrimestre del 2021 (prima e durante la diffusione della pandemia covid-19). I nostri dati documentano un incremento significativo delle infezioni ematiche da Klebsiella pneumoniae resistente ai carbapenemici e un incremento dell'uso e dei costi per ceftazidime/avibactam.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: The Value of Neutrophil-To-Lymphocyte Ratio for Evaluating Blood Stream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae: A Retrospective Cohort Study. (Pubmed Central) - Mar 30, 2022
The NLR on the 4th day is a readily available and independent prognostic biomarker for patients with CRKP BSI. This marker may have the potential for use in evaluating the efficacy of different anti-infection therapy strategies at an early stage.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
@InYourFAECIUM Ceftazidime/Avibactam? Thoughts? (Twitter) - Mar 29, 2022
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
My first thought was PrintScrn. My second thought was ceftaz-avi. (Twitter) - Mar 29, 2022
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Providentia in dose dependent range is suggestive of ESBL. Ceftazidime Avibactam? (Twitter) - Mar 29, 2022